Talk:Ezetimibe/simvastatin

From Wikipedia, the free encyclopedia

This is the talk page for discussing improvements to the Ezetimibe/simvastatin article.
Please sign and date your posts by typing four tildes (`~~~~`). Put new text under old text. Click here to start a new topic. New to Wikipedia? Welcome! Ask questions, get answers. This is not a forum for general discussion about the article's subject.	Be polite Assume good faith No personal attacks Be welcoming	Article policies No original research Neutral point of view Verifiability

	Ezetimibe is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome.
B	This article has been rated as B-Class on the quality scale.
Mid	This article has been rated as mid-importance for this Project's importance scale.

My question is about the possible side effects. I started taking Vytorin a couple of weeks ago. Within a short period I noticed an increase in the volume of my tinnitus (ringing in the ears) and a seemingly increased problem hearing. I have had the tinnitus for many years and had learned to cope with it but, it has increased a good deal. Has anyone else had a similar experience. My email is daviswd@charter.net.

My question is regarding stopping the drug. After 2 months of taking vitorin everything looks wonderful. What happens if I stop taking?Template:Unigned2

Has no perminant effects, so if discontinued then the cholesterol/lipid profile reverts back to its pre-treatment level. For the benefits of reduced cholesterol, this, like all other lipid therapies, needs to be continued indefinitely.David Ruben ^Talk 17:47, 15 July 2007 (UTC)

[edit] Ezetimibe/simvastatin and psoriasis

My mother has recently prescribed Ezetimibe/simvastatin and has noticed a flair up of her psoriasis I am hoping that some one may be able to through some light on this for me. My mother is 75 and is suffering from this infliction would love to be able to help her:)Template:Iunsigned2

Wikipedia is not a forum nor somewhere to seek medical advice. Suggest she asks her doctor. For research see if anything under "psoriasis simvastatin" and "psoriasis ezetimibe" search strings on searching PubMed, for which go to this search page.David Ruben ^Talk 14:00, 10 February 2008 (UTC)

[edit] changes regarding statement on the IMPROVE-IT trial

Vytorin is currently undergoing drug trials on patients with extremely high cardiovascular risk who have been in hospital with cardiac problems in the past 10 days. It is not being tested on the lower risk patients with raised cholesterol even though these represent the overwhelming majority of patients said to benefit from this kind of therapy

I am going to move this to its own section, as it does not belong under contraindications...

Also, I am revising this statement to reflect a more neutral POV.

Some background info: It is true that the IMPROVE-IT trial (which this statement presumably refers to) is testing the drug on patients who have been stabilized for an acute coronary syndrome, and are therefore high-risk. However, I would not say that these subjects represent an overwhelming minority of Vytorin's target base. The "lower risk" patients that this Wikier refers to are not as low risk as they seem, and there is abundant clinical evidence as well as pathogenetic plausibility to support that assessment. While I agree that a trial involving patients without a history of an ACS event would be ideal, I believe that the evidence strongly suggests that the disparity between the risk profiles of the study subjects and the drug's target audience is exaggerated by the above statement.

Additionally the 10-day enrollment period is largely irrelevant to the study's conclusions; the IMPROVE-IT trial design calls for a follow-up period of 30 months. This needs to be clarified.

--shrimppesto (talk) 07:05, 17 May 2008 (UTC)